Application of Single-Molecule Amplification and Resequencing Technology for Broad Surveillance of Plasma Mutations in Patients with Advanced Lung Adenocarcinoma

详细信息    查看全文

• 作者：Zheng Wang^&lowast ; ; Gang Cheng^&dagger ; ; Xiaohong Han^&Dagger ; ; Xinlin Mu^§ ; ; Yuhui Zhang^¶ ; ; Di Cui^&lowast ; ; Chang Liu^‖ ; Li Zhang^&lowast ; &lowast ; ; Zaiwen Fan^&dagger ; &dagger ; ; Lingyun Ma^&Dagger ; &Dagger ; ; Li Yang^&lowast ; ; Jing Di^&lowast ; ; David S. Cram^§ ; § ; ; Yuankai Shi^&Dagger ; ; ^{syuankaipumc@126.com} ; Dongge Liu^&lowast ; ; ^{liudongge@sohu.com}
• 刊名：The Journal of Molecular Diagnostics
• 出版年：2017
• 出版时间：January 2017
• 年：2017
• 卷：19
• 期：1
• 页码：169-181
• 全文大小：1284 K
• 卷排序：19

文摘

Liquid biopsy to access the circulating tumor DNA is a promising surrogate for invasive tumor genotyping. We designed a multiplex assay based on circulating single-molecule amplification and resequencing technology (cSMART) to simultaneously detect and quantitate hot spot EGFR, KRAS, BRAF, ERBB2, and ALK plasma DNA variants in 103 patients with advanced lung adenocarcinoma. In validation studies using an analytical mutation standard, the sensitivity of the assay for EGFR mutation detection was at least 0.1% and specificity was 100%. The diagnostic detection sensitivity was one mutant molecule per 2 mL of plasma. The most frequently detected plasma mutations were EGFR variants L858R (21.4%), exon 19 deletions (19.4%), T790M (9.7%), and KRAS G12X variants (9.7%). Rarer were BRAF V600X (1.95%) and ERBB2 exon 20 (0.97%) variants. In single samples, four novel EGFR exon 19 deletions, one KIF5B-ALK, and two EML4-ALK variants were also detected. From comparisons of 103 matched plasma and tumor specimen genotypes, 75 (72.8%) were concordant, 9 (8.8%) were partially concordant, and 19 (18.4%) were discordant. Overall, the combined positive and negative concordance rate for detection of each oncogenic variant exceeded 90%. On the basis of these findings, we propose that cSMART displays the diagnostic hallmarks of a comprehensive plasma genotyping assay, with potential application for precisely monitoring changes in plasma mutation levels in response to targeted drug therapy.